Theodore Schroeder
2021
In 2021, Theodore Schroeder earned a total compensation of $1.2M as Chief Executive Officer at Nabriva Therapeutics AG, a 25% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $302,993 |
|---|---|
| Salary | $594,170 |
| Stock Awards | $307,850 |
| Other | $32,287 |
| Total | $1,237,300 |
Schroeder received $594.2K in salary, accounting for 48% of the total pay in 2021.
Schroeder also received $303K in non-equity incentive plan, $307.9K in stock awards and $32.3K in other compensation.
Rankings
In 2021, Theodore Schroeder's compensation ranked 8,010th out of 12,406 executives tracked by ExecPay. In other words, Schroeder earned more than 35.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,010 out of 12,406 | 35th |
Division Manufacturing | 3,542 out of 5,494 | 36th |
Major group Chemicals And Allied Products | 1,575 out of 2,369 | 34th |
Industry group Drugs | 1,400 out of 2,090 | 33rd |
Industry Pharmaceutical Preparations | 1,038 out of 1,537 | 33rd |
Source: SEC filing on July 11, 2022.
Schroeder's colleagues
We found two more compensation records of executives who worked with Theodore Schroeder at Nabriva Therapeutics AG in 2021.